These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11675518)

  • 1. Lung cancer.
    Evans TL; Lynch TJ
    Oncologist; 2001; 6(5):407-14. PubMed ID: 11675518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
    Belani CP
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
    Ramanathan RK; Belani CP
    Semin Oncol; 1997 Aug; 24(4):440-54. PubMed ID: 9280224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.
    Goffin J; Lacchetti C; Ellis PM; Ung YC; Evans WK;
    J Thorac Oncol; 2010 Feb; 5(2):260-74. PubMed ID: 20101151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
    Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
    J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
    Bunn PA
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
    Socinski MA; Shea TC
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of unresectable non-small-cell lung cancer].
    Ueoka H
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):356-61. PubMed ID: 10740628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for advanced non-small cell lung cancer: standards.
    Manegold C
    Lung Cancer; 2001 Dec; 34 Suppl 2():S165-70. PubMed ID: 11720760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
    Rigas JR
    Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
    Novello S; Le Chevalier T
    Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.